As part of our ongoing aim to bring you reports of new developments, we have added a review which summarises two papers published from the CheckMate 8HW randomised, open-label, phase III trial. The first paper compares the use of the immune checkpoint inhibitors nivolumab (NIVO) plus ipilimumab (IPI) with chemotherapy as first-line therapy in patients with metastatic mismatch repair deficient/microsatellite instability-high colorectal cancer, and the second paper compares NIVO plus IPI versus NIVO alone regardless of prior systemic treatment.
Independent commentary for the review has been provided by Professor Jeanne Tie who is the lower gastrointestinal medical oncology and research Lead at the Peter MacCallum Cancer Centre, and senior research fellow at the Walter and Eliza Hall Institute, Melbourne, Australia.
Please login below to download this issue (PDF)